The Alex’s Lemonade Stand Foundation (ALSF) is offering a specialised research grant aimed at tackling an inherited condition that significantly increases the risk of blood cancers, particularly haematologic malignancies, in children and their families.
The primary objective of this grant is to fund projects that uncover biological mechanisms in cancer that are “druggable”—that is, targets that can be addressed with medication. Ultimately, the goal is to advance the development of preventive therapies capable of halting disease progression before blood cancer begins.
Scope of inquiry
A key research focus is on clonal haematopoiesis linked to inherited mutations in the RUNX1 gene. Applicants are encouraged to explore how additional acquired mutations interact with these inherited variants to trigger malignant cell growth — a discovery that could pave the way for preventive treatments
The grant also supports studies examining whether emerging cellular clones are protective and how premalignant clones adapt to inflammation. Insights from such studies could inspire innovative approaches—such as modulating inflammation—to delay or even prevent the onset of blood cancers.
Funding benefits
Eligible investigators may request up to $250,000 in direct costs over a two-year period, with a maximum of $125,000 per year. Proposed budgets must align with the project’s scope and objectives. Continued funding depends on demonstrated progress through required interim and annual reports.
Deadline
Applications close on December 11, 2025. Interested researchers can apply via the Alex’s Lemonade Stand Foundation website.
Explore our Opportunities page for more global research opportunities.
Summary not available at this time.
